Drug reference

insulin glulisine

Short-acting insulin analogue · Antidiabetic agent

Short-acting insulin analogueAntidiabetic agent

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

12 major

SEVERE in our sources

PREGNANCY

—

not curated

Top interactionssee all 12 →

CinoxacinSevereDatabaseDDInter
CiprofloxacinSevereDatabaseDDInter
DelafloxacinSevereDatabaseDDInter
EnoxacinSevereDatabaseDDInter

Mechanism

Insulin glulisine is a genetically modified insulin analogue where glutamic acid replaces lysine at B29 and lysine replaces asparagine at B3. These substitutions result in a reduction in self-association and rapid dissociation into active monomers, leading to rapid absorption and a shorter duration of action compared to regular insulin.

Indications

Type 1 diabetesType 2 diabetesControl prandial rise in blood glucoseUsed in insulin pump for treatment of diabetes

Pharmacokinetics

Onset

5-15 min

Peak effect

0.5-1.5 h

Side effects

Common

Hypoglycemia

Drug interactions

Cinoxacin

Severe

Database

Drug interaction classified as: antagonism

Source: DDInter

Ciprofloxacin

Severe

Database

Drug interaction classified as: antagonism

Source: DDInter

Delafloxacin

Severe

Database

Clinical effect not specified

Source: DDInter

Enoxacin

Severe

Database

Clinical effect not specified

Source: DDInter

Gatifloxacin

Severe

Database

Clinical effect not specified

Source: DDInter

Gemifloxacin

Severe

Database

Clinical effect not specified

Source: DDInter

Grepafloxacin

Severe

Database

Clinical effect not specified

Source: DDInter

Levofloxacin

Severe

Database

Clinical effect not specified

Source: DDInter

Lomefloxacin

Severe

Database

Clinical effect not specified

Source: DDInter

Moxifloxacin

Severe

Database

Clinical effect not specified

Source: DDInter

Nalidixic Acid

Severe

Database

Clinical effect not specified

Source: DDInter

Norfloxacin

Severe

Database

Clinical effect not specified

Source: DDInter

Related guidelines

Type 2 diabetes in adults

RSSDI · Endocrinology · 2022

Type 2 diabetes in adults

ADA · Endocrinology · 2022

Glucose monitoring in diabetes

RSSDI · Endocrinology · 2024

Diabetes management during Ramadan

ADA · Endocrinology · 2025

Type 2 diabetes in adults

ICMR · Endocrinology · 2022

Ask House about insulin glulisine

Continue into a citation-backed clinical answer with the drug context already attached.

Open in workspace Ask House about this drug

Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team